LeMaitre Vascular (NASDAQ:LMAT) Issues Q3 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its third quarter 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.660-0.710 for the period, compared to the consensus estimate of 0.730. The company issued revenue guidance of $66.3 million-$68.3 million, compared to the consensus revenue estimate of $69.0 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.840-2.940 EPS.

LeMaitre Vascular Trading Up 2.1%

Shares of LeMaitre Vascular stock traded up $2.17 during trading on Tuesday, reaching $105.78. 402,218 shares of the company were exchanged, compared to its average volume of 254,478. The business has a 50-day moving average price of $97.27 and a 200-day moving average price of $99.90. The firm has a market capitalization of $2.42 billion, a price-to-earnings ratio of 39.03, a P/E/G ratio of 2.81 and a beta of 0.52. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. LeMaitre Vascular has a twelve month low of $79.39 and a twelve month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. During the same quarter in the prior year, the firm posted $0.48 earnings per share. The company’s quarterly revenue was up 11.1% on a year-over-year basis. Sell-side analysts anticipate that LeMaitre Vascular will post 3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on LMAT shares. Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Barrington Research reaffirmed an “outperform” rating and issued a $120.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, June 3rd. Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Citizens Jmp increased their price objective on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Finally, Wells Fargo & Company lifted their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,881 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the transaction, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bridget A. Ross sold 5,044 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total value of $560,388.40. Following the completion of the sale, the director directly owned 3,942 shares of the company’s stock, valued at approximately $437,956.20. The trade was a 56.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 54,453 shares of company stock worth $5,906,174 over the last quarter. 7.40% of the stock is currently owned by insiders.

Institutional Trading of LeMaitre Vascular

Hedge funds and other institutional investors have recently modified their holdings of the stock. Illinois Municipal Retirement Fund increased its holdings in LeMaitre Vascular by 1.1% in the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock valued at $906,000 after purchasing an additional 123 shares during the period. NewEdge Advisors LLC raised its position in shares of LeMaitre Vascular by 4.6% during the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock worth $256,000 after acquiring an additional 139 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of LeMaitre Vascular by 0.4% in the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after acquiring an additional 155 shares during the period. Equitable Holdings Inc. boosted its holdings in LeMaitre Vascular by 1.4% in the fourth quarter. Equitable Holdings Inc. now owns 14,469 shares of the medical instruments supplier’s stock valued at $1,173,000 after acquiring an additional 205 shares during the last quarter. Finally, California State Teachers Retirement System boosted its holdings in LeMaitre Vascular by 1.7% in the second quarter. California State Teachers Retirement System now owns 18,721 shares of the medical instruments supplier’s stock valued at $1,555,000 after acquiring an additional 316 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.